adult patients with influenza virus infection
Conditions
Interventions
long-acting neuraminidase inhibitor laninamivir octanoate treatment group
zanamivir hydrate treatment group
Sponsors
Kameda Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Eligible patients are as follows; - patients who are diagnosed as influenza virus (A or B) infection using a rapid diagnostic kit - patients who have axillary temperatures of 37.5 celsius degree or higher measured at clinic - patients who present within 48 hours of the onset of influenza symptoms - patients who provide written informed consent - age: 20-65 old - patients who can use inhaling devices
Exclusion criteria
Exclusion criteria: Patients are to be excluded from the trial; - if they reported influenza symptoms and had been treated with any antibiotics or antivirus medications within 1 week before enrollment, - if they had any chronic respiratory disease (bronchial asthma, chronic obstructive pulmonary disease)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the time to alleviation of influenza illness, which was defined as the interval between the start of the trial treatment and the start of the first 24 hour period in which influenza symptoms have improved to absent or mild | — |
Secondary
| Measure | Time frame |
|---|---|
| the time to alleviation of influenza illness, which was defined as the interval between the start of the trial treatment and the start of the first 24 hour period in which axillary temperatures have returned to 36.9 celsius degree | — |
Countries
Japan
Contacts
Public ContactTadanori SASAKI
Kameda Medical Center Pharmacy Department
Outcome results
None listed